Last year, in May, the foreign parent of Fresenius Kabi, an Indian oncology drugs company, announced its intention to sell up to 15% promoter stake and reduce its shareholding to 75% via one or more OFS.
first published: Jun 22, 2013 02:50 pm
A collection of the most-viewed Moneycontrol videos.
